In the U.S., about 15.1 million people have an alcohol use disorder and about 4.8 million misuse opioids. This session focuses on the pharmacotherapy of alcohol and opioid use disorders. The faculty will describe and contrast naltrexone and acamprosate treatments for alcohol use disorder and discuss the use of buprenorphine/naloxone to treat opioid use disorder.
This presentation will provide an overview of existing trends in addictive disorders with an emphasis on screening, brief interventions and referrals to treatment (SBIRT) practices that every primary care provider should practice. A review of FDA-approved medications and evidence-based psychosocial practices will be presented. Finally, special emphasis will be placed on describing office-based tools that can be used to identify and prevent prescription opiate abuse.